(Reuters) - Biotech MiMedx Group Inc ( MDXG.O) said on Thursday it had replaced its chief financial officer and would restate financial statements following an internal investigation into its sales and distribution practices, sending shares 25 percent lower.
MiMedx to restate financial statements, replaces CFO
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться